Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

The Evolution of Antibodies into Versatile Tumor-Targeting Agents | Synapse

January 1, 2005Open Access

The Evolution of Antibodies into Versatile Tumor-Targeting Agents

MLMichael Z. LinStratford University MTMichael A. TeitellCalifornia NanoSystems Institute GSGary J. SchillerAPLA Health

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Cyr61 may contribute to the malignant progression of gastric cancer by promoting tumor cell motility/invasion through up-regulation of the functional COX-2 via an integrin alphavbeta3/NF-kappaB-dependent pathway.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Lin et al. (Sat,) studied this question.

synapsesocial.com/papers/69debaf4afb501b9b6558ba5 https://doi.org/https://doi.org/10.1158/1078-0432.129.11.1